BN Business News
Ajouter votre entreprise →
Cette traduction est en cours de préparation. En attendant, nous affichons temporairement la version originale en anglais.

Entreprise · 26/06/20251 min de lecture

Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Muscular Dystrophy Newborn Screening Test

Traduction automatique locale · Langue originale de la source

Résumé

The Food and Drug Administration (FDA, the Agency, or we) is classifying the muscular dystrophy newborn screening test into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for the muscular dystrophy newborn screening test's classification. We are taking this action because we have determined that classifying the device into class II (special controls) will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.

Langue originale de la source: Federal Register — Food and Drug AdministrationOuvrir le communiqué original →

Explorer les analyses

Analyses business →